Editorial Database
FDA Warning Letters: Compounded GLP-1 Telehealth Providers
An independently maintained, primary-source compilation of FDA warning letters issued to telehealth companies marketing compounded semaglutide, tirzepatide, and other GLP-1 products. Every entry links to the original letter on fda.gov.
Data as of April 6, 2026 · Report a missing letter
What this database is — and what it isn't
An FDA warning letter is the agency's principal means of notifying a company that the agency considers one or more of its products, practices, or marketing claims to be in violation of the Federal Food, Drug, and Cosmetic Act. The letter is a public document and appears on fda.gov.
A warning letter is not a recall, a fine, a criminal charge, or a finding of illegal activity. It is the start of a regulatory conversation. Companies typically have 15 working days to respond, and FDA may issue a close-out letter once the agency is satisfied that the cited issues have been corrected.
We compile these letters because they are the best public signal of which compounded-GLP-1 telehealth companies have drawn FDA scrutiny. We do not editorialize about whether a company is "bad." We quote FDA language and link to the source.
17 warning letters in our database
| Date | Company | Subject | FDA Letter |
|---|---|---|---|
| Mar 5, 2026 | Novo Nordisk Inc. | Postmarketing Adverse Drug Experience Reporting Requirements | #717576 ↗ |
| Feb 20, 2026 | Join Josie | Compounded GLP-1 marketing and labeling concerns | #717986 ↗ |
| Feb 20, 2026 | FitRxFitRx LLC | Compounded GLP-1 marketing and labeling concerns | #717987 ↗ |
| Feb 20, 2026 | Kin Meds | Compounded GLP-1 marketing and labeling concerns | #721450 ↗ |
| Feb 20, 2026 | MeasuredBetter Health Labs Inc | Compounded GLP-1 marketing and labeling concerns | #721454 ↗ |
| Feb 20, 2026 | Refills HealthRefills Health LLC | Compounded GLP-1 marketing and labeling concerns | #721475 ↗ |
| Feb 20, 2026 | BlueFitMD | Compounded GLP-1 marketing and labeling concerns | #721446 ↗ |
| Feb 20, 2026 | Premium HealthPremium Health Management Inc. | False & Misleading Claims/Misbranded | #721474 ↗ |
| Feb 20, 2026 | ZappyKare Solutions, LLC | False & Misleading Claims/Misbranded | #717991 ↗ |
| Feb 20, 2026 | SkinnyRxLean Rx, Inc. | False & Misleading Claims/Misbranded | #717989 ↗ |
| Feb 20, 2026 | StrutStrut Health, LLC | False & Misleading Claims/Misbranded | #721448 ↗ |
| Feb 20, 2026 | WeightCareWeightless Medical LLC | False & Misleading Claims/Misbranded | #721478 ↗ |
| Feb 20, 2026 | VIV RXViv Health, Inc. | False & Misleading Claims/Misbranded | #721818 ↗ |
| Feb 20, 2026 | ZeussZeuss LLC | False & Misleading Claims/Misbranded | #717985 ↗ |
| Feb 20, 2026 | IvimIvim Services LLC | False & Misleading Claims/Misbranded | #721816 ↗ |
| Jan 20, 2026 | GenoGenix LLC | Compounding Pharmacy/Adulterated Drug Products | #718739 ↗ |
| Dec 1, 2025 | Apothecary Pharma, LLC | Compounding Pharmacy/Adulterated Drug Products | #717972 ↗ |
Mar 5, 2026 · #717576
Novo Nordisk Inc.
Postmarketing Adverse Drug Experience Reporting Requirements
View details →
Feb 20, 2026 · #717986
Join Josie
Compounded GLP-1 marketing and labeling concerns
View details →
Feb 20, 2026 · #717987
FitRx
FitRx LLC
Compounded GLP-1 marketing and labeling concerns
View details →
Feb 20, 2026 · #721450
Kin Meds
Compounded GLP-1 marketing and labeling concerns
View details →
Feb 20, 2026 · #721454
Measured
Better Health Labs Inc
Compounded GLP-1 marketing and labeling concerns
View details →
Feb 20, 2026 · #721475
Refills Health
Refills Health LLC
Compounded GLP-1 marketing and labeling concerns
View details →
Feb 20, 2026 · #721446
BlueFitMD
Compounded GLP-1 marketing and labeling concerns
View details →
Feb 20, 2026 · #721474
Premium Health
Premium Health Management Inc.
False & Misleading Claims/Misbranded
View details →
Feb 20, 2026 · #717991
Zappy
Kare Solutions, LLC
False & Misleading Claims/Misbranded
View details →
Feb 20, 2026 · #717989
SkinnyRx
Lean Rx, Inc.
False & Misleading Claims/Misbranded
View details →
Feb 20, 2026 · #721448
Strut
Strut Health, LLC
False & Misleading Claims/Misbranded
View details →
Feb 20, 2026 · #721478
WeightCare
Weightless Medical LLC
False & Misleading Claims/Misbranded
View details →
Feb 20, 2026 · #721818
VIV RX
Viv Health, Inc.
False & Misleading Claims/Misbranded
View details →
Feb 20, 2026 · #717985
Zeuss
Zeuss LLC
False & Misleading Claims/Misbranded
View details →
Feb 20, 2026 · #721816
Ivim
Ivim Services LLC
False & Misleading Claims/Misbranded
View details →
Jan 20, 2026 · #718739
GenoGenix LLC
Compounding Pharmacy/Adulterated Drug Products
View details →
Dec 1, 2025 · #717972
Apothecary Pharma, LLC
Compounding Pharmacy/Adulterated Drug Products
View details →
How to read an FDA warning letter
Each FDA warning letter follows a standard structure: an opening paragraph identifying the company and the violations FDA is alleging, a numbered list of specific concerns (citing the relevant FDCA sections), and a closing paragraph explaining what the company must do to respond.
For compounded GLP-1 letters, the most common citations are under FDCA section 503A (the framework for traditional 503A compounders) and section 503B (for outsourcing facilities). Letters often reference unapproved new drug claims, misbranding, or use of bulk drug substances not on FDA's approved list.
A warning letter is the start, not the end, of an FDA enforcement process. We track status on each letter — "active" means the letter has not been formally closed out by FDA. We update entries when FDA publishes a close-out letter or withdraws the warning.
Editorial Disclaimer
FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. We compile this database as a public service and link to the original FDA letter for every entry. If you believe an entry here is inaccurate or out of date, please contact us.